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Abstract 
Objectives: Currently, there are no published randomised controlled veterinary trials 
evaluating the efficacy of anti-epileptic medication in the treatment of myoclonic seizures. 
This study aimed to evaluate the efficacy of phenobarbital and levetiracetam in the 
management of myoclonic seizures. 
Methods: This prospective randomised open-label trial compared the efficacy and 
tolerability of levetiracetam (20mg/kg q8h) to phenobarbital (3 to 5 mg/kg q12h) in cats 
with suspected feline audiogenic reflex seizures (FARS), that experienced myoclonic 
seizures on ≥12 days during a prospective 12-week baseline period. This was followed by 
a 4-week titration phase (until a therapeutic serum concentration of phenobarbital was 
achieved) and a 12-week treatment phase. 
Results: Of 68 cats randomised, 57 (levetiracetam, n = 28; phenobarbital, n = 29) were 
evaluable. A reduction of ≥50% in the number of myoclonic seizure days was seen in 100% 
of patients in the levetiracetam group and in 3% of patients in the phenobarbital group (P 
< 0.001) during the treatment period. Levetiracetam-treated cats were more likely to 
respond to treatment than those receiving phenobarbital. Levetiracetam-treated cats had 
higher freedom from myoclonic seizures (50.0% vs 0%; P < 0.001) during the treatment 
period. The most common adverse events were lethargy, inappetance and ataxia, with no 
difference in incidence between levetiracetam and phenobarbital. Adverse events were 
mild and transient with levetiracetam but persistent with phenobarbital. 
Conclusions: These results suggest that levetiracetam is an effective and well-tolerated 
treatment for cats with myoclonic seizures and is more effective than phenobarbital. 
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Whether it will prevent the occurrence of generalised tonic clonic seizures and other 
behavioural abnormalities if used early in the course of FARS is not yet clear. 
270 words 
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Introduction 
Feline audiogenic reflex seizures (FARS) represent a collection of seizure patterns, with 
the major characteristic being a geriatric-onset (>10 years) of auditory-induced, myoclonic 
seizures1. FARS occurs in pedigree and non-pedigree cats, but among the pedigrees, the Birman 
breed is over-represented1. Avoiding certain sounds can reduce the seizures, although owners 
reported that it is difficult to avoid noises, and the loudness of the sound also seemed to increase 
the severity of seizures1. A pattern of audiogenic kindling was observed in which myoclonic 
seizures develop after numerous daily sound exposures and results in the spread of a seizure 
discharge from brainstem to forebrain structures (i.e. the hippocampus, amygdale, and neocortex) 
after repetitive stimulation inducing seizures of another type2,3. In the case of FARS, these are 
generalized tonic-clonic seizures (GTCS)1. 
Myoclonus may only be one part of an epilepsy syndrome, and several problems regarding 
treatment exist. This is also true of FARS, where myoclonic seizures appear to the most common 
type. Not all antimyoclonic drugs are antiepileptic, and only some antiepileptic drugs (AEDs) are 
antimyoclonic. In addition, many of the myoclonic epilepsies reported in humans are refractory to 
drug treatment. No study has investigated treatment response in cats with FARS. 
Levetiracetam is a novel AED that was approved at the turn of the century for the treatment 
of partial epilepsies with or without secondary generalisation. It is structurally related to piracetam, 
which is commonly used in humans to treat myoclonic seizures. Levetiracetam is efficacious in the 
treatment of myoclonus and progressive myoclonic epilepsies4-10. 
In the face of availability of newer AEDs such as levetiracetam, there is need to reassess 
the role of first generation AEDs in the treatment of myoclonic epilepsy. The majority of cats 
suffering from FARS suffer myoclonic and/or GTCS as part of their syndrome. This provides a 
unique opportunity to assess the efficacy of antimyoclonic effect of medication. The objective of 
this study was to explore whether levetiracetam or phenobarbital monotherapy were effective 
  
6 
options in the management of FARS, and hence to determine whether older AEDs, such as 
phenobarbital, have a role in the treatment of feline myoclonic seizures. 
 
Materials and Methods 
 
Study design 
This prospective, multi-centre, randomised, controlled, open-label study was conducted 
between February 2014 and April 2015 and co-ordinated at Davies Veterinary Specialists. 
Following a 12-week baseline period, cats were randomly allocated to receive levetiracetam or 
phenobarbital. Directions regarding the dosage (3 – 5 mg/kg q12h PO for phenobarbital and 20 – 
25 mg/kg q8h PO for levetiracetam) were given via e-mail or phone to the attending veterinarian. 
In the case of phenobarbital, a blood sample was collected two weeks after commencing medication 
to assess the serum concentration of the drug. If the dose was sub-therapeutic the dosage was 
increased accordingly and a blood sample was collected two weeks later until a mid-range 
therapeutic concentration was achieved (20 - 35 µg/mL or 86.5 - 151 µmol/l). In both treatment 
groups, a titration period of 4 weeks was included to allow the medication to reach steady-state 
concentrations. This period was extended in individual cats as required until therapeutic 
concentrations of phenobarbital were achieved. Following the titration period, a 12-week treatment 
period was observed. Patients were discontinued from the study if their owners withdrew consent, 
or for lack of efficacy for safety reasons. These were either due to abhorrent adverse effects or a 
severe increase in seizure frequency as judged by the investigator. 
 
Patients 
Cats with a diagnosis of FARS were included. Cats were recruited from the pool of owners 
that had previously contacted the primary author (ML) regarding a questionnaire-led phenotypic 
study1 including new owners that had contacted our centre since completion of the original study. 
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Diagnosis was achieved by video evidence of audiogenic myoclonic seizures. For inclusion, cats 
had to have experienced 12 or more days of myoclonic seizures during the prospective 12-week 
baseline period, have been on no previous anti-epileptic medication and fulfil the criteria of the 
previously described phenotype for FARS1. Patient exclusion criteria included any concurrent 
disease that could represent a contraindication to the use of levetiracetam or phenobarbital, notably 
known pre-existing hepatic or renal dysfunction, previous or current treatment with anti-epileptic 
medication, or signs suggestive of a progressive brain lesion. All owners gave informed consent 
before participation in the study. 
 
Assessments 
Owners were requested to complete a seizure diary during the whole period of the study. 
They recorded the date, number, and type of seizure (GTCS, myoclonic or absence) on daily record 
cards. The primary investigator collated and confirmed this information with each owner and 
recorded it in an electronic spreadsheet. Owners were also instructed to include a record describing 
any signs of illness, change in activity or attitude. During the study, owners were requested to get 
on with daily life as normal and to make no attempts to produce the sounds responsible for eliciting 
their cats’ seizures. 
The primary efficacy variable was the responder rate for myoclonic seizure days per week. 
Responders were defined as those experiencing a ≥ 50% decrease in the mean number of myoclonic 
seizure days per week during the treatment period compared to baseline. Myoclonic seizure 
frequency was not selected as an efficacy variable as these seizures are frequently difficult to 
quantify owing to their repetitiveness. Secondary efficacy variables included mean percentage 
reduction from baseline in myoclonic seizure days/week; rates of seizure freedom from myoclonic 
seizures; and the total number of myoclonic seizure free days.  
Adverse events were also recorded; their intensity and relationship to study medication 
were judged by the primary investigator (ML) in conjunction with the attending veterinarian. 
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Seizure Classification 
The definition of a GTCS is straightforward but includes variations beginning with a clonic 
or myoclonic phase. A myoclonic seizure was defined as a sudden, brief, muscular jerk involving 
the limbs, neck or trunk (singly or in some combination) occurring as a single or irregularly 
recurrent event. An absence seizure was considered as the occurrence of an abrupt, transient 
apparent loss of consciousness with no motor activity. These definitions are in accordance with the 
ILAE classification of epileptic syndromes11. 
 
Statistical Analysis 
On the basis of a two-group continuity corrected χ2 test, a sample size of 72 cats (36 cats 
randomly assigned to each treatment group) was considered sufficient to attain a statistical power 
of 90% for detecting a treatment difference of 40% in responder rate, assuming responder rates of 
70% and 30% in the levetiracetam and phenobarbital groups respectively, and using a 5% two-
sided significance level. 
Two sample t-tests and Fisher’s exact tests were used to compare demographics and 
baseline seizure history between the treatment groups. Patients failing to complete the study were 
excluded from further analysis. 
The treatment OR and 95% CI for the responder rate in myoclonic seizure days per week 
was calculated using a 2x2 contingency table and Fisher’s exact test. Seizure freedom rates were 
compared between treatment groups using Fisher exact test. 
The secondary efficacy variables between treatment arms were tested with a Fisher’s exact 
test for categorical variables and the Wilcoxon rank sums test for continuous variables 
A significance level of P < 0.05 was established for all analyses. 
 
Results 
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Patient disposition 
Ninety-seven cats underwent baseline assessment, of which 29 were found to be ineligible 
(12 did not meet the inclusion criteria, 12 cats were lost to follow-up, 3 cats died and 2 owners 
withdrew consent) and were not randomised (figure 1). Therefore 68 cats were randomised (34 to 
levetiracetam and 34 to phenobarbital). Baseline demographic characteristics of cats that were 
randomly assigned to each of the study groups are given in table 1. There was no difference between 
treatment groups. All cats experienced myoclonic seizures during baseline with 57/68 (84%) 
experiencing GTCS in addition, during the study period. Only five cats (7%) had a single reported 
absence seizure during baseline. 
The mean age of the cats at seizure onset was 15 years (median 15 years; range, 10-19 
years). Thirty-six cats were female (69%; 25/36 neutered) and 32 were male (88%; 28/32 neutered). 
Breeds comprised of 36 domestic short-haired (DSH), 17 Birman cats, 5 Burmese cats, 3 domestic 
long-haired (DLH), 2 Bengal cats, and one of each of Maine coon, British Shorthair, European 
shorthair, Norwegian Forest cat and Birman cross. 
A total of 57 cats (84%) completed the study (figure 1). Efficacy analysis therefore 
included a total of 57 cats (28 receiving levetiracetam; 29 receiving phenobarbital). Daily 
phenobarbital dose (n=29) was 3.125 mg/kg/day (median; range 1.67 - 7.5 mg/kg/day) with a 
phenobarbital serum concentration of 27.7 µg/mL (mean; range 20.4 - 33.2 µg/mL). The 
levetiracetam dose (n=28) was 62.5 mg/kg/day (median; range 60 - 93.75 mg/kg/day). 
Four cats died during the course of the treatment period. Two cats in each of the 
levetiracetam and phenobarbital groups died during the treatment period and were not included in 
the efficacy analyses. Death was due to euthanasia in all cases with three cats exhibiting progressive 
non-seizure forebrain signs and one cat in the levetiracetam group having sudden and severe 
dyspnoea. No post-mortems were performed. Three owners of cats in the levetiracetam group 
withdrew consent and all cited the frequency with which medication was administered as their 
reason. One cat was lost to follow-up in the levetiracetam group. Three further cats were excluded 
  
10 
from the phenobarbital group during the treatment period; one owner withdrew consent, one cat 
was lost to follow-up and one cat developed severe lethargy and was withdrawn. 
 
Baseline parameters 
Table 2 summarises the results for the comparisons of baseline myoclonic seizure 
frequency in both groups. There was no significant difference between the groups. 
 
Efficacy 
Table 3 summarises these results. During the 12-week treatment period, all levetiracetam-
treated cats (100%) and 1 of 29 phenobarbital-treated cats (3%) exhibited at least a 50% reduction 
from baseline in the number of myoclonic seizures per week (OR = 0, 95% CI: 0 to 0.0096; P < 
0.001). 
There was a significant difference in those cats experiencing a ≥ 50% decrease in 
myoclonic seizure days per week compared to baseline between cats receiving levetiracetam and 
phenobarbital (mean % reduction in seizures [± SD] levetiracetam, 98.8 [4.7]; phenobarbital, 2.8 
[23.3], P < 0.001). 
During the 12-week treatment period, 14/28 cats (50%) receiving levetiracetam were free 
of myoclonic seizures compared with no cats receiving phenobarbital (OR = 0, 95% CI; 0 to 0.14, 
P < 0.001).  
There was a significant difference in the total number of myoclonic seizure free days 
compared to baseline between treatment groups (mean % increase in seizure free days [± SD] 
levetiracetam, 95.7 [8.80]; phenobarbital, -57.0 [54.5], P < 0.001). 
Regarding GTCS, these were infrequent with 11/68 having no GTCS during baseline (5/34 
in the levetiracetam group and 4/34 in the phenobarbital group). The median number of GTCS 
during baseline for all cats was one (range, 0-3). During treatment, 44/68 cats experienced GTCS 
(22 cats in each group) and the median number of GTCS during treatment for all cats was 0 (range, 
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0-1). For levetiracetam-treated cats; 23 had a decrease in the number of GTCS on treatment and 11 
were excluded either due to lack of GTCS at baseline or failure to complete the study. Regarding 
phenobarbital-treated cats; 23 had a decrease in GTCS on treatment, two remained with the same 
GTCS frequency on treatment, and nine were excluded due to lack of GTCS at baseline or failure 
to complete the study. No absence seizures were reported during the treatment period in any cat. 
Consequently, statistical analysis of GTCS and absence seizures was not performed. 
 
Safety Analysis 
Safety analysis showed that 24% of cats (16/68) experienced apparent adverse events and 
that the majority were mild to moderate in nature. Treatment-related adverse events were reported 
by owners of five cats (5/34; 18%) in the levetiracetam group and included lethargy (4/5), mild 
inappetance (3/5), ataxia (2/5) and polydipsia (1/5). These signs resolved without any change in 
dosage after approximately 2 weeks. One cat experienced a serious adverse event (severe lethargy 
and ataxia) leading to cessation of treatment. Adverse effects were reported in 11/34 cats (32%) 
receiving phenobarbital, including lethargy (8/11), ataxia (4/11), weakness (1/11) and behavioural 
changes (1/11). In one case the lethargy was severe enough to warrant withdrawal from the study. 
These reported signs were relatively persistent in this population, resolving in only 2/11 cats during 
the treatment period. 
 In an extension of this study, five patients switched to levetiracetam therapy after receiving 
phenobarbital because their owners desired improved seizure control. Of these patients, 3/5 have 
reported no further myoclonic seizures and 2/5 have just one myoclonic seizure per week. 
 
Other Information 
Owners of cats in the phenobarbital group perceived no benefit from using the medication 
with only adverse effects reported (see above). All owners with cats receiving levetiracetam 
commented on their cat appearing brighter and more responsive during the treatment period 
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following initial transient effects of sedation and lethargy when reported. Fifteen of 28 owners 
(54%) had not realised their cat’s mentation had altered until observing the effects during treatment.  
 
Discussion 
Feline audiogenic reflex seizures (FARS) have provided a unique opportunity to compare 
the efficacy of phenobarbital and levetiracetam in management of myoclonic seizures. Many 
owners and veterinarians alike have traditionally considered these seizures to be an age-related 
finding or potentially that they were associated with concurrent renal or cardiac disease. In making 
this false assumption this has provided a pool of drug-naïve patients on which to base the grounds 
of our study. We have therefore been able to evaluate the antimyoclonic efficacy of phenobarbital 
and levetiracetam in the management of FARS. It has long been suggested that medical 
management for myoclonic seizures contrasts to that for GTCS. This study provides the first 
veterinary evidence that levetiracetam is superior to phenobarbital in the management of myoclonic 
seizures. 
The pharmacokinetics of levetiracetam in 10 healthy cats was evaluated following the 
disposition of a single dose of the drug via oral and intravenous routes12. Although limited 
information on the pharmacokinetics has been published, this study supported the use of 
levetiracetam at 20mg/kg three times daily. The only efficacy study of levetiracetam in cats 
reported its use as an adjunct to phenobarbital in 10 epileptic cats with GTCS13. The study reported 
a reduction of more than 50% in seizure frequency in 7/10 cats following administration and the 
medication appeared well tolerated. Our results support the tolerability, but appear to show a more 
dramatic response to levetiracetam when used as an anti-myoclonic medication. 
Levetiracetam is indicated in people as a monotherapy in the treatment of partial-onset 
seizures and as adjunctive treatment of myoclonic seizures and GTCS. In a recent double-blind, 
placebo-controlled trial, levetiracetam (3000 mg/day) was shown to be highly effective as 
adjunctive therapy in 120 idiopathic generalised epilepsy patients aged 12 to 65 years with 
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uncontrolled myoclonic seizures. Just over half (58.3%) of these patients achieved a >50% 
reduction in myoclonic seizure days per week, compared with 23.3% in the placebo group 4. 
Another double-blind, placebo-controlled trial has shown adjunctive levetiracetam to be effective 
in controlling GTCS, myoclonic seizures and all seizures type in patients with idiopathic 
generalised epilepsy compared with placebo15. The median percentage reduction in seizure days 
per week between the prospective baseline period and treatment period was 62.8% for levetiracetam 
and 24.7% for placebo. The results of these two double-blind, placebo-controlled studies are in line 
with the findings of open-label studies in people16-19, confirming the usefulness of levetiracetam in 
idiopathic generalised epilepsies with myoclonic seizures. 
It is still not clear how levetiracetam exerts its antiepileptic effect. It does not, like many 
other AEDs, bind to the GABAA-benzodiazepine receptor complex, does not inhibit voltage-gated 
sodium channels and does not inhibit low-voltage-activated Ca2+-channels20. It has been found to 
bind to synaptic vesicle glycoprotein SV2A, which is one of three isoforms of the SV2 protein, and 
the isoform most widely distributed in the brain20. SV2A is thought to inhibit presynaptic Ca2+ 
channels, so reducing neurotransmitter release21. There is a strong correlation between affinity of 
levetiracetam for this binding site and the seizure protection given to audiogenic mouse models of 
epilepsy20. Thus, although no molecular mechanisms of action are described for levetiracetam, it is 
possible that its anti-myoclonic actions are mediated via the SV2A protein. 
Two studies have provided evidence that levetiracetam, unlike other AEDs, may have 
modulatory effects on activity-dependent plasticity and its behavioural consequences. Löscher and 
colleagues demonstrated that administration of levetiracetam during induction of kindling resulted 
in a persistent reduction in after-discharge duration, even after discontinuation of treatment in rats22. 
A second study investigated a strain of rats that developed spontaneous seizures in adulthood23. 
They were given long-term levetiracetam before these seizures developed. Even though these 
seizures continued to develop, a significant decrease in the frequency and duration of both tonic 
and absence seizures was noted compared with untreated animals. These data suggest that 
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levetiracetam has a different spectrum of action to other AEDs, which may relate to the novel 
mechanism of action via SV2A. The observation in our study of cats appearing brighter and more 
responsive provides tentative evidence to suggest levetiracetam influences behavioural 
consequences of FARS. However, it cannot be excluded that this change in demeanour may simply 
be the result of freedom from the myoclonic seizures and hence lack of post-ictal signs. 
Rarely, patients have only myoclonic seizures as a manifestation of FARS, but more 
frequently, the myoclonus may predominate, and GTCS may be infrequent1. The predominant 
seizure type in the cats of our study was myoclonic, while over 80% also had GTCS and less than 
10% had absence seizures. Whether a build-up of myoclonic jerks eventually leads to a GTCS is 
not entirely proven. Many cats are reported to be indifferent to myoclonic jerks with owners 
frequently electing to monitor their frequency1. In some, however, these constitute a concern when 
owners observe a train of myoclonic jerks culminating in a single GTCS. This observation, 
combined with the available data suggesting FARS is a progressive disorder1 infers that early 
medical intervention is an advantage and when prescribed, owners perceive their cats to be brighter 
as a result. 
Two unanswered questions from these results are, in our view: one, will levetiracetam 
prevent GTCS in the same way it prevents myoclonus? Potentially the answer to this is ‘yes’, 
although statistical evidence in this study is lacking. Two, will levetiracetam prevent progression 
to GTCS if used as an early interventional therapy? Again, the results here cannot prove this but 
previous work22,23 may suggest this is a possibility. 
 
Conclusion 
In conclusion, when myoclonus is frequent in cats with FARS and when agreement exists 
between the owner and the veterinarian that medical treatment is justified, treatment with 
levetiracetam is likely to be effective. Whether it will prevent the occurrence of GTCS if used early 
in the course of the disease is not clear. 
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Figure 1: Trial profile. 
 
Tables 
 
  
Levetiracetam (n= 
34) 
Phenobarbital 
(n=34) P-value 
Age, years 18 (12-23) 19 (13-22) 0.09 
Weight, kg 4 (2-8) 4 (1-10) 0.29 
Breed   0.97 
DSH 17 19  
DLH 2 1  
Birman 8 9  
Other 34 34  
Sex   0.70 
F 17 15  
FN 13 9  
M 17 19  
MN 11 14  
Age at onset of seizures, years 15 (10-19) 16 (10-19) 0.10 
Seizure duration, years 3 (2-4) 3 (2-4) 1.00 
    
Table 1: Baseline characteristics of cats allocated to each treatment group. Median (range). DLH, 
domestic long-hair; DSH, domestic short-hair; F, female; kg, kilograms; M, male; N, neutered. 
 
 Levetiracetam Group 
(n=34) 
Phenobarbital Group 
(n=34) 
P Value 
Myoclonic seizure frequency per 
day 
2.52 (0-18) 2.3 (0-17) 0.248 
Total myoclonic seizure free days 33.4 (22-53) 35 (21-43) 0.348 
Myoclonic seizures per week 2.5 (0-57) 2.3 (0-51) 0.248 
Myoclonic seizure days per week 4.2 (0-7) 4.1 (0-7) 0.348 
Table 2: Frequency of myoclonic seizures at baseline in both treatment groups. Median (range). 
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 Levetiracetam Group 
(n=28) 
Phenobarbital Group 
(n=29) 
P Value 
Number of cats achieving ≥50% 
reduction from baseline in the 
number of myoclonic seizures per 
week 
28 (100%) 1 (3%) <0.001 
Mean percentage reduction from 
baseline in the number of myoclonic 
seizures per week 
98.8 (±4.7) 2.8 (±23.3) <0.001 
Number of cats achieving 
myoclonic seizure freedom 
14 (50%) 0 (0) <0.001 
Mean percentage increase in 
myoclonic seizure free days 
95.7 (±8.8) -57 (±54.5) <0.001 
Table 3: Efficacy of levetiracetam and phenobarbital in the management of feline audiogenic reflex 
myoclonic seizures. Number (percentage); mean (±standard deviation). 
